On January 18, 2023 Pluristyx and panCELLa today are excited to reported the granting of a patent used in their universal, off-the-shelf, induced pluripotent stem cells (iPSCs) (Press release, panCELLa, JAN 18, 2023, View Source [SID1234626300]). The Great Britain Patent Office on January 4, 2023 issued patent number GB2588249B extending panCELLa’s protection of its induced Allogeneic Cell Tolerance (iACT Stealth) technology (WO/2018/227286) to the United Kingdom.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The iACT Stealth technology, exclusively licensed by panCELLa from Mount Sinai Hospital, allows clinical-grade cell therapy products and tissues to avoid rejection by the patient after transplant and reduces or eliminates the need for the immunosuppression currently required for tissue transplants. The iACT Stealth technology is available for evaluation under the ‘Try- before-you-buy’ research evaluation model as a stand-alone product or in combination with FailSafe and SafeHarbor platform technologies.
Mahendra Rao, Co-Chairman of the Board at panCELLa and Chief Scientific Officer at Pluristyx commented, "As we integrate Pluristyx and panCELLa into a single entity, we have continued to fund and protect the development of our industry-leading platform technologies for use in iPSCs. We are extremely pleased with the grant of claims by the Great Britain patent office to protect our iACT Stealth technology. iACT Stealth is immediately available in custom or catalog format for quick evaluation and adoption by our academic and industry partners."
Benjamin Fryer, Chief Executive Officer at Pluristyx, said: "At the new Pluristyx, we believe that the unique combination of iACT Stealth, FailSafe, and SafeHarbor technologies are the cornerstone of future cell therapies. With a single cell line and license, a sponsor can now develop, manufacture, and commercialize their universal cell or tissue therapy using our off-the-shelf technologies and gene-edited cells. This unique combination of proprietary gene edits simplifies manufacturing, reduces business and process costs, and offers a chance to revolutionize iPSC-based therapeutic development."